Increasing Failure of Miltefosine in the Treatment of Kala-azar in Nepal and the Potential Role of Parasite Drug Resistance, Reinfection, or Noncompliance | Zendy

Suman Rijal | Zendy; Bart Ostyn | Zendy; Surendra Uranw | Zendy; Keshav Rai | Zendy; Narayan Raj Bhattarai | Zendy; Thomas P. C. Dorlo | Zendy; Jos H. Beijnen | Zendy; Manu Vanaerschot | Zendy; Saskia Decuypere | Zendy; Subodh Sagar Dhakal | Zendy; Murari Lal Das | Zendy; Prahlad Karki | Zendy; Rupa Rajbhandari Singh | Zendy; Marleen Boelaert | Zendy; JeanClaude Dujardin | Zendy

Open Access

Increasing Failure of Miltefosine in the Treatment of Kala-azar in Nepal and the Potential Role of Parasite Drug Resistance, Reinfection, or Noncompliance

Author(s) -

Suman Rijal,

Bart Ostyn,

Surendra Uranw,

Keshav Rai,

Narayan Raj Bhattarai,

Thomas P. C. Dorlo,

Jos H. Beijnen,

Manu Vanaerschot,

Saskia Decuypere,

Subodh Sagar Dhakal,

Murari Lal Das,

Prahlad Karki,

Rupa Rajbhandari Singh,

Marleen Boelaert,

JeanClaude Dujardin

Publication year - 2013

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cit102

Subject(s) - medicine , miltefosine , drug resistance , visceral leishmaniasis , linezolid , leishmaniasis , clinical trial , drug , meglumine antimoniate , immunology , pharmacology , vancomycin , microbiology and biotechnology , biology , genetics , bacteria , staphylococcus aureus

Miltefosine (MIL), the only oral drug for visceral leishmaniasis (VL), is currently the first-line therapy in the VL elimination program of the Indian subcontinent. Given the paucity of anti-VL drugs and the looming threat of resistance, there is an obvious need for close monitoring of clinical efficacy of MIL.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research